Valuation: VolitionRx Limited

Market Cap 11.66M 10.21M 9.41M 8.73M 16.58M 1.11B 16.81M 113M 43.83M 546M 43.8M 42.84M 1.89B P/E 2026 *
-0.63x
P/E 2027 * -1.01x
Enterprise Value 11.66M 10.21M 9.41M 8.73M 16.58M 1.11B 16.81M 113M 43.83M 546M 43.8M 42.84M 1.89B EV / Sales 2026 *
4.71x
EV / Sales 2027 * 2.03x
Free-Float
91.38%
Yield 2026 *
-
Yield 2027 * -
1 day-2.14%
1 week-3.52%
Current month+1.48%
1 month-1.44%
3 months-59.49%
6 months-75.25%
Current year-73.20%
1 week 1.32
Extreme 1.32
1.48
1 month 1.17
Extreme 1.17
1.56
Current year 1.17
Extreme 1.17
7.73
1 year 1.17
Extreme 1.17
16
3 years 1.17
Extreme 1.17
31
5 years 1.17
Extreme 1.17
82.8
10 years 1.17
Extreme 1.17
136.8
Manager TitleAgeSince
Chief Executive Officer 55 05/10/2011
Director of Finance/CFO 56 31/01/2021
Chief Tech/Sci/R&D Officer 49 31/03/2024
Director TitleAgeSince
Director/Board Member 55 05/10/2011
Director/Board Member 77 05/10/2011
Director/Board Member 64 08/10/2019
Date Insider Type Main position Quantity % Market Cap.
03-16Tax

Executive/Senior Manager

5,251 0.0039%
03-16Tax

General Counsel

7,003 0.0052%
03-16Tax

Chief Technology Officer

5,310 0.0039%
Change 5-day change 1-year change 3-year change Capi.($)
-2.14%-3.52%-89.83%-94.96% 11.66M
+2.06%-3.24%+121.11%+150.82% 4.55B
+1.30%+0.70%+83.56%+256.20% 3.39B
-1.23%+4.39%-26.36%-39.18% 2.07B
-1.74%+0.83%+149.71%-37.67% 1.92B
+1.34%+1.23%+60.65%+254.12% 1.51B
-1.57%-7.04%+128.46%-50.79% 891M
-1.02%+3.75%-9.78%+39.66% 874M
+0.64%+7.22%-34.19%-15.82% 498M
+0.24%+8.77%+3.31% - 473M
Average -0.22%+1.17%+38.66%+51.38% 1.62B
Weighted average by Cap. +0.48%+1.06%+77.14%+112.30%

Financials

2026 *2027 *
Net sales 2.48M 2.17M 2M 1.86M 3.52M 236M 3.57M 23.92M 9.31M 116M 9.3M 9.1M 402M 5.73M 5.02M 4.62M 4.29M 8.15M 547M 8.26M 55.36M 21.55M 268M 21.53M 21.06M 931M
Net income -22.2M -19.45M -17.91M -16.62M -31.57M -2.12B -32M -214M -83.44M -1.04B -83.38M -81.55M -3.6B -19.62M -17.18M -15.83M -14.69M -27.9M -1.87B -28.27M -189M -73.73M -919M -73.68M -72.06M -3.18B
Net Debt - -
Logo VolitionRx Limited
VolitionRx Limited is a multi-national company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer, and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.
Employees
67
Date Price Change Volume
06/07/26 US$1.370 -2.14% 146,337
02/07/26 US$1.400 +2.94% 208,730
01/07/26 US$1.360 +0.74% 201,077
30/06/26 US$1.350 -4.93% 163,419
29/06/26 US$1.420 +10.94% 301,479
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.400USD
Average target price
16.97USD
Spread / Average Target
+1,111.86%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VNRX Stock